Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 6/20 | 0.55 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10112811 | 0.98 | IDO1 (0.57) | IDO1HPGDAKR1C3ALDH1A1RXFP1 | |
| SCHEMBL29930390 | 0.92 | ALDH1A1 (0.62) | IDO1HPGDAKR1C3ALDH1A1NPC1 | |
| SCHEMBL1171241 | 0.92 | ALDH1A1 (0.62) | IDO1HPGDAKR1C3ALDH1A1NPC1 | |
| SCHEMBL4733957 | 0.84 | IDO1 (0.50) | IDO1HPGDAKR1C3ALDH1A1RXFP1 | |
| SCHEMBL29277841 | 0.83 | ALDH1A1 (0.57) | HPGDAKR1C3ALDH1A1NPC1RAB9A | |
| SCHEMBL85591 | 0.83 | ALDH1A1 (0.57) | HPGDAKR1C3ALDH1A1NPC1RAB9A | |
| SCHEMBL11933644 | 0.83 | IDO1 (0.54) | IDO1HPGDAKR1C3ALDH1A1NPC1 | |
| SCHEMBL11142367 | 0.82 | ALDH1A1 (0.74) | HPGDAKR1C3ALDH1A1NPC1RAB9A | |
| SCHEMBL2728631 | 0.81 | LMNA (0.58) | HPGDAKR1C3ALDH1A1NPC1RAB9A | |
| SCHEMBL4461794 | 0.81 | AKR1C3 (0.55) | HPGDAKR1C3ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6858616-B2 | Nitrogen containing heterobicycles as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-02-22 | — | — | US | disclosed |
| EP-1140941-B1 | NITROGEN CONTAINING HETEROBICYCLES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20030069237-A1 | Nitrogen containing heterobicycles as factor Xa inhibitors | FEVIG JOHN M (US) | 2003-04-10 | — | — | US | disclosed |
| US-6413980-B1 | INHIBITORS OF TRYPSIN-LIKE SERINE PROTEASE ENZYMES; ANTICOAGULANTS; THROMBOEMBOLIC DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-07-02 | — | — | US | disclosed |
| EP-1140941-A1 | NITROGEN CONTAINING HETEROBICYCLES AS FACTOR XA INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039131-A1 | NITROGEN CONTAINING HETEROBICYCLES AS FACTOR XA INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069237-A1 | Nitrogen containing heterobicycles as factor Xa inhibitors | F12, F11, F10 | IDO1 2086/4885HPGD 929/4885AKR1C3 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.